ANL 31.47 Increased By ▲ 0.79 (2.57%)
ASC 14.10 Decreased By ▼ -0.84 (-5.62%)
ASL 23.80 Decreased By ▼ -0.10 (-0.42%)
AVN 94.75 Increased By ▲ 2.75 (2.99%)
BOP 9.14 No Change ▼ 0.00 (0%)
BYCO 9.78 Decreased By ▼ -0.47 (-4.59%)
DGKC 134.80 Decreased By ▼ -0.80 (-0.59%)
EPCL 52.25 Increased By ▲ 2.25 (4.5%)
FCCL 24.90 Increased By ▲ 0.28 (1.14%)
FFBL 24.80 Increased By ▲ 0.55 (2.27%)
FFL 15.20 Decreased By ▼ -0.40 (-2.56%)
HASCOL 10.75 Increased By ▲ 0.01 (0.09%)
HUBC 84.80 Decreased By ▼ -0.40 (-0.47%)
HUMNL 7.00 Decreased By ▼ -0.35 (-4.76%)
JSCL 24.94 Increased By ▲ 0.09 (0.36%)
KAPCO 37.40 Decreased By ▼ -0.45 (-1.19%)
KEL 4.08 Decreased By ▼ -0.07 (-1.69%)
LOTCHEM 14.45 Decreased By ▼ -0.33 (-2.23%)
MLCF 46.95 Increased By ▲ 0.35 (0.75%)
PAEL 37.19 Decreased By ▼ -1.06 (-2.77%)
PIBTL 11.68 Decreased By ▼ -0.12 (-1.02%)
POWER 10.22 Decreased By ▼ -0.28 (-2.67%)
PPL 90.65 Increased By ▲ 0.10 (0.11%)
PRL 25.30 Decreased By ▼ -0.80 (-3.07%)
PTC 8.75 Decreased By ▼ -0.20 (-2.23%)
SILK 1.41 Increased By ▲ 0.01 (0.71%)
SNGP 38.50 Increased By ▲ 0.40 (1.05%)
TRG 141.60 Increased By ▲ 0.50 (0.35%)
UNITY 29.75 Decreased By ▼ -1.75 (-5.56%)
WTL 1.54 Decreased By ▼ -0.03 (-1.91%)
BR100 4,912 Decreased By ▼ -23.77 (-0.48%)
BR30 25,332 Decreased By ▼ -71.47 (-0.28%)
KSE100 45,593 Decreased By ▼ -271.59 (-0.59%)
KSE30 19,056 Decreased By ▼ -117.19 (-0.61%)
Markets

S&P 500 struggles for direction as new COVID worries outweigh stimulus-passage boost

  • That resurgence continues to swell, infecting 214,000 Americans every day, prompting mandatory shutdowns and pushing hospitals to capacity.
23 Dec 2020

NEW YORK: The S&P 500 was essentially unchanged on Tuesday as worries over a new variant of COVID-19 and downbeat economic data dampened enthusiasm over the passage of a long-awaited pandemic relief bill in Washington.

The Dow was lower, while Apple Inc helped fuel the tech-heavy Nasdaq's advance.

"The market trades in anticipation of an event," said Robert Pavlik, senior portfolio manager at Dakota Wealth in Fairfield, Connecticut. "And once you reach that point as we did yesterday with the passing of the stimulus bill, the market is looking for the next catalyst to drive it forward."

Apple was an outlier amid a broad sell-off, gaining 3.6pc and providing the biggest lift to all three major U.S. stock indexes on news of the company's plans to roll out an electric passenger vehicle by 2024.

Overnight, Congress passed a pandemic relief package worth $892 billion after months of a partisan tug-of-war, aimed at propping up an economic recovery faltering under the weight of restrictions aimed at containing a coronavirus resurgence.

That resurgence continues to swell, infecting 214,000 Americans every day, prompting mandatory shutdowns and pushing hospitals to capacity.

A fast-spreading new variant of the virus discovered in Britain has brought movement in and out of the UK to a halt and sent vaccine makers Pfizer Inc and Moderna Inc scrambling to ensure their drugs were effective against it.

Fears of the coronavirus and optimism about an eventual economic recovery made for extreme volatility on Wall Street in 2020, with the S&P 500 logging daily gains or losses of 2pc or more over 40 times in the year so far, the most in over a decade.

"The changes that have occurred in the world, I don't think anyone who's working today has seen anything like this," Pavlik added. "Nobody was prepared to deal with this situation where nearly the whole world was shut down."

On the economic front, consumer confidence unexpectedly dropped while sales of pre-owned U.S. homes posted their first decline in six months.

The Dow Jones Industrial Average fell 105.17 points, or 0.35pc, to 30,111.28, the S&P 500 gained 1.18 points, or 0.03pc, to 3,696.1 and the Nasdaq Composite added 57.69 points, or 0.45pc, to 12,800.21.

Of the 11 major sectors in the S&P 500, only tech and real estate were green.

Tesla Inc fell 2.4pc, extending its slide on its second day as a S&P 500 constituent.

Peloton Interactive Inc jumped 10.7pc as brokers hiked their price targets on the stock on the heels of the company's announcement that it would buy peer Precor in a deal worth $420 million.

Amgen Inc slid 2.5pc and was among the heaviest drags on the Dow, after disappointing results from a late-stage study of an asthma drug developed in a partnership with British drugmaker AstraZeneca Plc.

Declining issues outnumbered advancing ones on the NYSE by a 1.19-to-1 ratio; on Nasdaq, a 1.17-to-1 ratio favored advancers.

The S&P 500 posted 21 new 52-week highs and one new low; the Nasdaq Composite recorded 294 new highs and eight new lows.